β-Patchoulene 是一种具有口服活性的抗炎、抗氧化及抗凋亡 (apoptosis) 剂,可抑制 NF-κB、TLR4 和 cAMP/PKA/CREB 信号通路,激活 Sirt1/Nrf2 以及 AMPK 信号通路,并抑制 Fas/FasL、Caspase-3、ERK1/2、ROCK1/MLC2 等作用靶点,同时可调节细胞因子分泌、炎性细胞浸润、脂质过氧化、细胞极化、肠道菌群及脂质代谢,恢复屏障功能、线粒体功能与细胞活力,并对甜菜夜蛾幼虫具有驱避活性,因此可用于多种炎症性、缺血性、纤维化相关疾病以及肝细胞癌的相关研究。
产品编号: MS-N07986 CAS No.: 514-51-2 分子式: C15H24 分子量: 204.35
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
20mg
询价
询价

产品描述

β-Patchoulene 是一种具有口服活性的抗炎、抗氧化及抗凋亡 (apoptosis) 剂,可抑制 NF-κB、TLR4 和 cAMP/PKA/CREB 信号通路,激活 Sirt1/Nrf2 以及 AMPK 信号通路,并抑制 Fas/FasL、Caspase-3、ERK1/2、ROCK1/MLC2 等作用靶点,同时可调节细胞因子分泌、炎性细胞浸润、脂质过氧化、细胞极化、肠道菌群及脂质代谢,恢复屏障功能、线粒体功能与细胞活力,并对甜菜夜蛾幼虫具有驱避活性,因此可用于多种炎症性、缺血性、纤维化相关疾病以及肝细胞癌的相关研究。

生物实验数据

生物活性 β-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptosis agent that inhibits the NF-κB, TLR4, and cAMP/PKA/CREB signaling pathways, activates the Sirt1/Nrf2 and AMPK signaling pathways, and suppresses targets including Fas/FasL, Caspase-3, ERK1/2, and ROCK1/MLC2; it also modulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae, making it useful for research on various inflammatory, ischemic, and fibrosis-related diseases as well as hepatocellular carcinoma.
IC50 & Target

NF-κB

 

TLR4

 

PKA

 

SIRT1

 

AMPK

 

Caspase-3

 

ERK1

 

ERK2

 

ROCK-1

 

体外研究
(In Vitro)

β-Patchoulene (10-100 μmol/L) 对人 GES-1 胃上皮细胞无显著细胞毒性,最高浓度可达 80 μmol/L。
β-Patchoulene (10-40 μmol/L; 4 h pre-incubation, 24 h co-cultivation with ethanol) 预处理可显著提升乙醇损伤的人 GES-1 胃上皮细胞的细胞活力。
β-patchoulene (5-50 μM; 1 h) 通过增强 Nrf2 核转位和 HO-1 表达,同时抑制 NF-κB p-P65 表达,剂量依赖性地抑制 H/R 损伤培养巨噬细胞中的促炎细胞因子产生、氧化应激和细胞凋亡。
β-Patchoulene (0.1-160 μM; 24 or 48 h) 对大鼠肠上皮 IEC-6 细胞无细胞毒性。
β-Patchoulene (20-80 μM; 24 h) 可显著恢复经 5-Fluorouracil (HY-90006) 损伤的大鼠肠上皮 IEC-6 细胞的活力。
β-Patchoulene (20 μM; 24 h) 可抑制经 5-FU 处理的大鼠肠上皮 IEC-6 细胞中 AQP3 的表达,并使 cAMP/PKA/CREB 信号通路失活。
β-Patchoulene (10-100 μM; 24 h) 对人肝细胞 L02 细胞无细胞毒性,仅在 100 μM 时观察到显著的细胞毒性。
β-Patchoulene (40 μM; 24 h) 通过激活 AMPK 信号通路显著抑制游离脂肪酸诱导的人肝细胞 L02 脂质沉积.
β-Patchoulene (0.3125-20 μM;48 小时) 可呈剂量依赖性抑制人肝癌 Huh-7 与 MHCC97 细胞的活力及增殖能力。
β-Patchoulene (2.5 μM;48 小时) 可调控相关蛋白表达,抑制缺氧诱导的人肝癌 Huh-7、MHCC97 细胞增殖,促进细胞凋亡,阻滞细胞侵袭与上皮间质转化,并下调 NF-κB/HIF-1α 信号通路活性。
β-Patchoulene 是重组 DoPAES 蛋白催化反应的主要产物。

Cell Viability Assay

Cell Line: human GES-1 gastric epithelial cells (ethanol-induced injury)
Concentration: 10, 20, 40 μmol/L
Incubation Time: 4 h (pre-incubation); 24 h (co-cultivation with ethanol)
Result: Increased cell viability in ethanol-exposed GES-1 cells to 66.96% at 10 μmol/L.
Increased cell viability in ethanol-exposed GES-1 cells to 69.81% at 20 μmol/L.
Increased cell viability in ethanol-exposed GES-1 cells to 73.31% at 40 μmol/L.

Western Blot Analysis

Cell Line: Cultured Macrophages
Concentration: 5 μM, 50 μM
Incubation Time: 1 h (pre-incubation)
Result: Promoted nuclear Nrf2 translocation in H/R-injured macrophages in a dose-dependent manner.
Upregulated HO-1 protein expression in H/R-injured macrophages in a dose-dependent manner.
Inhibited NF-κB p-P65 protein expression in H/R-injured macrophages in a dose-dependent manner.

Cell Viability Assay

Cell Line: rat intestinal epithelial IEC-6 cells
Concentration: 0.1, 1, 10, 20, 40, 60, 80, 160 μM
Incubation Time: 24 h; 48 h
Result: Showed no cytotoxicity to IEC-6 cells at all tested concentrations over 24 and 48 h, with cell viability remaining near 100% relative to the control group.

Cell Viability Assay

Cell Line: 5-fluorouracil (5-FU)-injured rat intestinal epithelial IEC-6 cells
Concentration: 20, 40, 80 μM
Incubation Time: 24 h
Result: Significantly restored the viability of 5-FU-injured IEC-6 cells.

Western Blot Analysis

Cell Line: 5-FU-treated rat intestinal epithelial IEC-6 cells
Concentration: 20 μM
Incubation Time: 24 h (post 8-Br-cAMP induction)
Result: Suppressed overexpression of AQP3 and PKA, and inhibited phosphorylation of MEK1/2, MSK1, and CREB compared to the 5-FU-only group.
Had effects counteracted by the PKA agonist 8-Br-cAMP via upregulation of related protein expression or phosphorylation.

Cell Viability Assay

Cell Line: human hepatocyte L02 cells
Concentration: 10 μM, 20 μM, 40 μM, 80 μM, 100 μM
Incubation Time: 24 h
Result: Shows no significant reduction in cell viability at concentrations up to 80 μM relative to the normal control group.
Causes a significant decrease in cell viability at 100 μM concentration.

Cell Viability Assay

Cell Line: human hepatocellular carcinoma Huh-7, MHCC97 cells
Concentration: 0.3125, 0.625, 1.25, 2.5, 5, 10 μM
Incubation Time: 48 h
Result: Reduced the viability of Huh-7 and MHCC97 cells in a concentration-dependent manner.

Cell Proliferation Assay

Cell Line: human hepatocellular carcinoma Huh-7, MHCC97 cells
Concentration: 0.3125, 0.625, 1.25, 2.5, 5, 10 μM
Incubation Time: 48 h (treatment), followed by 2 weeks of culture
Result: Decreased the colony-forming ability of Huh-7 and MHCC97 cells in a concentration-dependent manner.

Apoptosis Analysis

Cell Line: hypoxia-induced human hepatocellular carcinoma Huh-7, MHCC97 cells
Concentration: 2.5 μM
Incubation Time: 48 h
Result: Significantly increased the apoptotic rate of hypoxia-induced Huh-7 and MHCC97 cells compared to the hypoxia-only group.
Downregulated the expression of the anti-apoptotic protein Survivin, which was upregulated by hypoxia.
体内研究
(In Vivo)

β-Patchoulene (2.5-10 mg/kg;口服;每日 1 次;连续 7 天) 对 LPS 诱导的雄性昆明小鼠急性肺损伤具有显著的保护作用,可通过抑制 NF-κB 信号通路、激活 Nrf2 信号通路及上调 miR-146a 表达。
β-Patchoulene (灌胃;每日给药,连续 7 天,剂量 10-40 mg/kg) 可呈剂量依赖性地保护雄性 Sprague Dawley 大鼠免受乙醇诱导的胃溃疡损伤,其作用机制涉及抗氧化、抗炎、抗凋亡及信号通路调控。
β-Patchoulene (0.2-1 mg/kg;侧脑室注射;CLP 术后立即单次给药) 可显著改善脓毒症相关性脑病小鼠模型的认知功能,减轻神经炎症与氧化应激,抑制小胶质细胞活化及 M1 型极化,增强 Sirt1/Nrf2/HO-1 通路活性,减少脾脏淋巴细胞凋亡。
β-Patchoulene (10-40 mg/kg;灌胃;每日;连续 7 天) 可剂量依赖性地抑制二甲苯诱导的 KM 小鼠耳肿胀。
β-Patchoulene (灌胃;每日 1 次;连续 7 天,剂量 10-40 mg/kg) 可剂量依赖性地降低醋酸诱导的 KM 小鼠血管通透性。
β-Patchoulene (灌胃;每日一次;连续 7 天,剂量 10-40 mg/kg) 可在角叉菜胶诱导的 KM 小鼠足肿胀模型中发挥强效的、剂量依赖性抗炎作用,其作用机制为抑制促炎介质、氧化应激及 NF-κB 信号通路。
β-Patchoulene (10 mg/kg;静脉注射;术前 2 小时单次给药) 预处理可通过减少肝酶释放、炎症反应、氧化应激和细胞凋亡,同时激活 Nrf2/HO-1 通路并抑制 NF-ƘB 信号传导,保护雄性 C57BL/6 小鼠免受肝脏缺血再灌注损伤。
β-Patchoulene (10 mg/kg;静脉注射;术前 1 h 单次预处理给药) 可对 Sprague-Dawley 大鼠的脑缺血再灌注损伤发挥神经保护作用,表现为梗死体积缩小、脑水肿减轻、神经功能缺损改善、细胞凋亡减少、炎症及氧化应激水平降低,其作用机制为抑制 TLR4/NF-κB 信号通路的激活。
β-Patchoulene (5-20 mg/kg;口服;每日一次;连续 7 天) 可通过抑制结肠渗漏、阻断炎症信号通路及恢复肠道微生物群稳态,呈剂量依赖性改善雄性 BALB/c 小鼠中 DSS 诱导的溃疡性结肠炎及继发性肝损伤,其中 20 mg/kg 剂量在所有检测终点中均展现出最显著的效果。
β-Patchoulene (10-40 mg/kg;口服;每日;连续 7 天) 可呈剂量依赖性改善 5-Fluorouracil (HY-90006) 诱导的雄性 Sprague Dawley 大鼠肠黏膜炎,其中 40 mg/kg 灌胃剂量在改善体况、肠道组织病理学表现、抑制炎症、修复黏液屏障,以及通过抑制 cAMP/PKA/CREB 信号通路降低 AQP3 表达方面的作用最强。
β-Patchoulene (40 mg/kg;口服;每日 1 次;连续 7 天) 可改善 5-Fluorouracil (HY-90006) 诱导的雄性 Sprague Dawley 大鼠肠黏膜炎。
β-Patchoulene (灌胃;每日;连续 4 周,剂量为 10-40 mg/kg) 可激活 AMPK 信号通路,抑制肝脏脂质合成并促进线粒体脂质氧化,显著缓解大鼠中由 HFD 诱导的 NAFLD。
β-Patchoulene (5-20 μmol/kg) 在缺氧裸鼠模型中呈剂量依赖性地抑制肝癌肿瘤生长、诱导肿瘤细胞凋亡、抑制上皮-间质转化,并使 NF-κB/HIF-1α 通路失活。

Animal Model: Kunming (KM) (male, 18-22 g, LPS-induced ALI)
Dosage: 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: p.o.; once daily; 7 days
Result: Decreased LPS-induced mouse mortality effectively.
Lessened pulmonary edema and improved multiple pathological lesions in lung tissues.
Downregulated pulmonary oxidative stress levels and inflammatory cytokine secretion.
Suppressed the activation of NF-κB inflammatory signaling pathway.
Promoted the activation of Nrf2 antioxidant signaling pathway.
Upregulated the expression level of miR-146a in lung tissues.
Animal Model: Sprague Dawley (male, 180-220 g, ethanol-induced gastric ulcer)
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.g.; daily; 7 days
Result: Reduced gastric ulcer area in a dose-dependent manner with obvious inhibition effect.
Lowered histological total microscopic score in a dose-dependent manner, alleviating epithelial damage and submucosal oedema.
Improved SOD activity, enhanced CAT activity, increased GSH level, decreased MDA level, and reduced serum levels of TNF-α, IL-1β and IL-6 at all doses.
Downregulated Fas, FasL, and caspase-3 IODs in a dose-dependent manner at all doses.
Inhibited increased p-p65/p65 and p-IκB/IκB ratios at the highest dose.
Enhanced p-ERK1/2/ERK1/2 ratio at the highest dose.
Upregulated c-fos mRNA, c-jun mRNA, and miR-21 expression at the highest dose.
Animal Model: C57BL/6 (male, 6-10 weeks old, sepsis associated encephalopathy induced by cecal ligation and puncture surgery)
Dosage: 0.2 mg/kg; 1 mg/kg
Administration: i.c.v.; single dose immediately post-CLP
Result: Elevated behavioral and cognitive related indicators at multiple time points after CLP operation at 1 mg/kg, and effectively raised the survival rate of model mice.
Reduced cerebral inflammatory factors and oxidative stress levels without affecting anti-inflammatory factor expression, and inhibited hippocampal microglial M1 polarization.
Regulated the expression of Sirt1/Nrf2 pathway-related proteins and relieved hippocampal neuronal apoptosis.
Alleviated systemic inflammatory response and suppressed splenic lymphocyte apoptosis.
Low-dose treatment could partially ameliorate cognitive dysfunction.
Animal Model: Kun Ming (KM) (male and female, 18-22 g)
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.g.; daily; 7 days
Result: Inhibited xylene-induced ear edema and acetic acid-triggered vascular permeability in a dose-dependent manner, and relieved carrageenan-caused paw edema with obvious long-term inhibitory effects.
Alleviated pathological swelling, tissue damage and inflammatory cell infiltration, and improved tissue fibrous structure.
Lowered paw tissue MDA and MPO contents effectively.
Reduced the release of multiple pro-inflammatory cytokines and inflammatory mediators.
Downregulated the expression levels of iNOS and COX-2 proteins.
Stabilized IκBα to block NF-κB signaling pathway activation and restrain nuclear translocation of p65.
Animal Model: C57BL/6 (male, 8-10 weeks old)
Dosage: 10 mg/kg
Administration: i.v.; single dose 2 hours before surgery
Result: Lowered serum ALT and AST levels and alleviated liver pathological injury in hepatic ischemia-reperfusion mice.
Inhibited hepatic inflammatory cytokine expression and reduced inflammatory factor-positive macrophages.
Mitigated hepatic oxidative stress and restrained hepatocyte apoptosis.
Suppressed M1 polarization of Kupffer cells.
Activated Nrf2/HO-1 antioxidant pathway and inhibited NF-κB p65 phosphorylation.
Animal Model: Sprague-Dawley (male, 8 weeks old, 80-120 g, middle cerebral artery occlusion for 2 h followed by 24 h reperfusion)
Dosage: 10 mg/kg
Administration: i.v.; single pretreatment dose 1 h before surgery
Result: Reduced cerebral infarct volume, brain edema and neurological deficits, and recovered mitochondrial membrane potential in cerebral ischemia-reperfusion injured rats.
Declined neuronal apoptosis rate, regulated BAX/Bcl-2 balance and lowered caspase-3 activity.
Downregulated inflammatory factor expression, relieved oxidative stress damage and improved antioxidant enzyme activity.
Blocked the TLR4/NF-κB pathway via modulating related protein expression and restricting p65 nuclear translocation.
Animal Model: BALB/c (male, 21-25 g, induced with 3% dextran sulfate sodium in drinking water ad libitum for 7 days)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: p.o.; daily; 7 days
Result: Improved general disease conditions and relieved colon tissue damage in a dose-dependent manner, and alleviated colon shortening at medium and high doses.
Inhibited intestinal cell apoptosis and upregulated intestinal barrier-related gene expression at medium and high doses.
Lowered colonic inflammatory mediators and adhesion molecule contents, and restrained multiple inflammatory signaling pathways.
Declined local and systemic lipopolysaccharide levels, and regulated various serum inflammatory and liver function related indicators.
Ameliorated liver inflammatory lesions and reduced hepatic inflammatory factor release in a dose-related way.
Restored intestinal microbial diversity and optimized gut flora structure at high dose.
Animal Model: Sprague Dawley (male, 180-220 g, 5-fluorouracil-induced intestinal mucositis)
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: p.o.; daily; 7 days
Result: Promoted body weight gain and improved food intake at medium and high doses, and relieved diarrhea symptoms at all doses in 5-FU induced model rats.
Optimized intestinal tissue morphological structure and alleviated intestinal pathological damage at all doses.
Regulated intestinal inflammatory factor levels effectively at medium and high doses.
Elevated intestinal mucin secretion and increased goblet cell quantity to enhance intestinal mucosal barrier function.
Downregulated the expression of related functional proteins and restrained the activation of multiple downstream signaling pathways in a dose-dependent manner.
Animal Model: Sprague Dawley (male, 180-220 g, 5-fluorouracil-induced intestinal mucositis)
Dosage: 40 mg/kg
Administration: p.o.; daily; 7 days
Result: Promoted body weight gain and improved food intake at medium and high doses, and relieved diarrhea symptoms at all doses in 5-FU induced model rats.
Optimized intestinal tissue morphological structure and alleviated intestinal pathological damage at all doses.
Reduced intestinal TNF-α, IL-1β, IL-6 and IL-10 contents obviously at medium and high doses.
Elevated intestinal MUC2 mucin level and goblet cell number to strengthen intestinal mucosal barrier function.
Downregulated the expression of related functional proteins and inhibited the activation of MEK/ERK/p38 signaling cascades at all doses with dose-dependent effects.
Animal Model: Sprague Dawley (male, 180−220 g, NAFLD induced by 60% fat high-fat diet for 4 weeks)
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.g.; daily; 4 weeks
Result: Reduced liver index without affecting body weight gain at low dose, while middle and high doses decreased both body weight gain and liver index in HFD-fed models.
Improved serum levels of ALT, AST, HDL-C, LDL-C, TG and TC, and lowered hepatic TG, TC and NEFA contents at all tested doses.
Alleviated hepatic pathological lesions and decreased lipid deposition area in liver tissues.
Suppressed the expression of hepatic lipid synthesis related proteins and genes including SREBP-1c, HMG-CR, FASN and SCD1, and regulated ACC1 phosphorylation level.
Elevated hepatic antioxidant capacity by decreasing MDA content and raising GSH-Px and SOD activities, and upregulated lipid oxidation markers SIRT1, PPARα and CPT-1a with no obvious influence on ACOX1 expression.
Activated AMPK signaling pathway by elevating p-AMPKα/AMPKα ratio and AMPKα mRNA expression in liver tissues in a dose-dependent manner.
性状 液体(密度:0.951±0.10 g/cm3)
颜色 Colorless to light yellow

化学信息

分子量 204.35
分子式 C15H24
CAS No. 514-51-2

储存&溶解度

储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.

β-Patchoulene 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础